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Introduction
The fixed-dose combination (FDC) of the inhaled 
corticosteroid (ICS) fluticasone propionate and 
long-acting β2-agonist (LABA) formoterol fuma-
rate, delivered via pressurized metered-dose 
inhaler (fluticasone/formoterol; Flutiform®) has 
been available in Europe for the treatment of 
asthma in adolescents and adults since 2012.1 
The efficacy and safety of fluticasone/formoterol 
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Abstract
Introduction: In recognition of the value of long-term real-world data, a postauthorization 
safety study of the inhaled corticosteroid (ICS) fluticasone propionate and long-acting β2-
agonist (LABA) formoterol fumarate (fluticasone/formoterol; Flutiform®) was conducted.
Methods: This was a 12-month observational study of outpatients with asthma aged ⩾ 12 
years in eight European countries. Patients were prescribed fluticasone/formoterol according 
to the licensed indication, and independently of their subsequent enrolment in the study. They 
were then treated according to local standard practice. The study objectives were to evaluate 
the safety and effectiveness of fluticasone/formoterol under real-world conditions.
Results: The safety population for this study comprised 2539 patients (mean age 47.7 years; 94.3% 
aged ⩾ 18 years; 63.4% female). Most patients (1538/2539, 60.6%) had switched to fluticasone/
formoterol from another ICS/LABA, primarily due to lack of efficacy (1150/2539, 45.3%). Three 
quarters (77.4%) of patients were treated for 12 months, and 80.6% continued fluticasone/
formoterol treatment after the study. Adverse events (AEs) occurred in 60.0% patients, and 
10.2% had AEs considered possibly related to fluticasone/formoterol [most commonly asthma 
exacerbation (2.0% patients), dysphonia (1.8%) and cough (1.1%)]. Thirty-six severe AEs, but 
no serious AEs, were considered possibly related to fluticasone/formoterol. The proportion of 
patients with controlled asthma (based on Asthma Control Test score ⩾ 20) increased from 29.4% 
at baseline to 67.4% at study end (last observation carried forward). The proportion of patients 
experiencing at least one severe exacerbation decreased from 35.8% in the year prior to enrolment 
to 9.8% during the study. Improvements from baseline to study end were also observed in Asthma 
Quality of Life scores and physician/patient reports of satisfaction with treatment.
Conclusion: In this real-world postauthorization safety study, fluticasone/formoterol 
demonstrated a safety profile consistent with that seen in controlled clinical trials, with 
effectiveness in improving asthma control.
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in asthma is supported by a comprehensive clini-
cal dataset.2–9 This includes demonstrated superi-
ority over placebo or the constituent monotherapies 
in mild–moderate and moderate–severe asthma,6,7 
comparable efficacy with other approved ICS/
LABA FDC products, though with a more 
rapid onset of bronchodilation than fluticasone/
salmeterol,2–4 and open-label data from up to 12 
months of treatment.9
Aside from data specifically relating to flutica-
sone/formoterol, the use of ICS and LABA in 
combination is supported by a wealth of preclini-
cal and clinical evidence. At the molecular level, a 
synergistic mechanism of action of ICS/LABA 
has been proposed on the basis of in vitro data.10,11 
In clinical trials, adding LABA to ICS has been 
shown to generate better asthma control than 
increasing the dose of ICS,12–16 and this strategy 
improves symptoms and lung function with a 
reduced risk of exacerbations.17 It has also been 
suggested that the provision of an ICS and a 
LABA in a single inhaler may also be associated 
with improved patient adherence relative to the 
treatments administered by separate inhalers.10,18,19 
Together, these lines of evidence are reflected in 
the 2017 Global Initiative for Asthma (GINA) 
guidelines, which advise that the preferred 
approach for the maintenance treatment of 
asthma in patients over the age of 12 not con-
trolled by low-dose ICS alone [with as-needed 
short-acting β2-agonist (SABA) as reliever] is to 
add a LABA.20
Although the value of fluticasone/formoterol and 
other ICS/LABA combinations in asthma man-
agement has been well established through robust 
clinical trials, the applicability of these data to 
real-world practice is inevitably limited by restric-
tions in the eligibility criteria of such trials. 
Exclusion of patients with comorbidities, for 
example, prevents trial data from reflecting this 
critical influence on the effectiveness and safety of 
a drug in practice. It has been reported that study 
populations participating in randomized con-
trolled trials (RCTs) in asthma typically represent 
less than 5% of the population for whom the 
products become licensed.21–23 Effective treat-
ment of asthma relies upon good inhaler tech-
nique, which is carefully controlled and supported 
by regular retraining in the RCT setting; this is 
often not reflective of real-world practice, in 
which poor inhaler technique is a recognized fac-
tor limiting the achievement of asthma control.22
In recognition of the discord between the man-
agement of asthma in clinical trial and real-world 
settings and as part of an agreed European Risk 
Management Plan (EU RMP), a non-interven-
tional postauthorization safety study [PASS; 
ENCePP EU PAS register number EUPAS4072; 
AFFIRM (Assessing Fluticasone propionate/
Formoterol In Real-life Maintenance treatment)] 
was conducted to determine the safety and effec-
tiveness of fluticasone/formoterol in clinical 
practice.
Methods
Study design
This PASS was designed to collect data on the 
safety and effectiveness of fluticasone/formoterol 
prescribed for outpatients with moderate to severe 
asthma aged ⩾ 12 years over a 12-month period. 
Participants were under the care of general prac-
titioners or respiratory physicians in primary or 
secondary care in eight European countries: 
Czech Republic, Denmark, France, Ireland, 
Norway, Slovak Republic, Sweden and the 
United Kingdom. Patients were treated with flu-
ticasone/formoterol according to the licensed 
indication, with data captured for 1 year from 
first on-study dose of fluticasone/formoterol.
The primary objective was to evaluate the safety 
of fluticasone/formoterol by collecting data on 
drug exposure and the frequency of adverse 
events (AEs) associated with the treatment. 
Secondary objectives were to assess the effective-
ness of fluticasone/formoterol treatment on 
asthma control under real-world conditions. The 
study was also intended to provide data on 
patients’ and physicians’ satisfaction with flutica-
sone/formoterol therapy.
Assessments
Demographic information, data on asthma his-
tory and the reason for initiation of fluticasone/
formoterol were recorded at the baseline visit. 
Details of asthma history included prior asthma 
treatment (in the last 30 days), asthma control 
status [according to Asthma Control Test 
(ACTTM) score], severe asthma exacerbations in 
the last 12 months and satisfaction with previous 
treatment. After the baseline visit, physicians’ vis-
its, diagnostic procedures and assessments were 
performed as clinically indicated in the opinion of 
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the treating physician and according to treatment 
guidelines. Data available at prespecified time-
points of 1, 3, 6, 9 and 12 months postbaseline 
were collected, including fluticasone/formoterol 
exposure (including dose change and reason for 
discontinuation). Data on AEs were collected via 
reports from participating patients (either sponta-
neous report or in response to physicians’ open 
questioning), as well as those detected by diag-
nostic procedures during routine clinical practice 
at the physicians’ discretion.
Asthma control was assessed by means of ACTTM 
scores (total plus component scores: ability to 
perform daily activities; shortness of breath; sleep 
disturbances due to asthma; necessity to use a 
rescue medication; subject assessment of asthma 
control). Asthma was defined as ‘controlled’ if the 
total ACTTM score was ⩾20, ‘somewhat con-
trolled’ if the score was 16–19, and ‘poorly 
controlled’ if the score was ⩽15.
On-study measurements of asthma-related medi-
cation use (including rescue medication use, anti-
biotics, systemic corticosteroids, etc.), 
concomitant diseases and medication, consulta-
tions and hospitalizations due to asthma, days of 
absence from work/school/college/university and 
inability to perform everyday activities due to 
asthma were also recorded. Lung function param-
eters [forced expiratory volume in 1 s (FEV1), 
forced vital capacity (FVC), FEV1/FVC ratio, 
and peak expiratory flow (PEF)] were monitored 
as both absolute and percent predicted values. 
Severe asthma exacerbations were recorded as 
AEs; a severe exacerbation defined as worsening 
of asthma that required either the use of systemic 
corticosteroids (oral or parenteral) related to the 
asthma exacerbation, or unscheduled medical 
consultation (hospitalization, unscheduled physi-
cian’s visit or emergency department visit) during 
which systemic corticosteroids were administered 
due to asthma symptoms. Asthma exacerbations 
treated with courses of corticosteroids separated 
by 1 week or more were treated as separate 
exacerbations.
Data were also collected on quality of life using 
the Asthma Quality of Life Questionnaire 
(AQLQ; total plus component scores: activities 
limitation; emotional function score; environ-
mental stimuli score; symptoms score), patient- 
and physician-rated satisfaction with treatment, 
and physicians’ estimates of patient adherence.
Study data were collated in electronic case report 
forms by investigator site staff.
Participants
Eligible patients had moderate to severe asthma 
and had been prescribed fluticasone/formoterol 
in accordance with the locally approved indica-
tion. As such, they were at least 12 years of age 
(male or female), with asthma that was not con-
trolled on ICS and ‘as required’ inhaled SABAs, 
or they had been switched to fluticasone/formo-
terol from another treatment with a fixed or a free 
ICS/LABA combination. Patients with contrain-
dications as laid out in the summary of product 
characteristics were excluded.24 Prescription of 
fluticasone/formoterol was initiated in normal 
clinical practice, and independent of patients’ 
subsequent enrolment in the study.
Written informed consent was obtained for all 
participants according to local requirements. 
Two sites withdrew from the study; data from 
these sites are not included.
Statistical analyses
The target study sample size was set at 2500 in 
order to provide adequate precision in estimating 
AE rates. Continuous variables were summarized 
using descriptive statistics; categorical data were 
summarized as number and percentage of patients 
with nonmissing data. All analyses were per-
formed on the safety population, which com-
prised all patients who received at least one dose 
of study medication during the observational 
period of the study.
For the safety analysis, treatment-emergent AEs, 
related AEs, severe AEs, AEs leading to death, 
serious AEs, AEs leading to discontinuation of 
the study, AEs requiring additional therapy, AEs 
leading to dose change, and AEs of special inter-
est were summarized. The annual rate of severe 
exacerbations was calculated for the period of 12 
months prior to study enrolment and during the 
study.
Treatment effectiveness was analysed based on 
ACTTM scores, AQLQ scores and lung function 
parameters. For these parameters, data available 
at each prespecified time point and at end of 
study, and corresponding changes from baseline, 
were summarized descriptively [including 95% 
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confidence intervals (CI) for the mean changes]. 
Changes from baseline were also analysed using 
the paired t test; given the non-interventional 
study design, these statistical tests were explora-
tory. In general, last observation carried forward 
(LOCF) imputation for missing data was used for 
the end-of-study analyses of effectiveness 
parameters.
Patient- and physician-rated treatment satisfac-
tion and physicians’ estimates of patient adher-
ence at each time point and end of study were 
summarized by frequency tables.
Results
Patients
A total of 2567 patients consented to participate 
in the study, and 2539 (98.9%) of these were 
included in the safety population. A summary of 
patient disposition is shown in Figure 1. Three 
quarters (1964, 77.4%) of the safety population 
completed the 12-month observational period of 
the study and remained on fluticasone/formoterol 
during this time. Of those who discontinued from 
the study or fluticasone/formoterol prematurely 
(575, 22.6%), the most common primary reasons 
for discontinuation were loss to follow up (224 
patients, 39.0%) and AEs (135, 23.5%). Of the 
patients who completed the study, nearly all 
(1893/1964, 96.4%) continued to be prescribed 
fluticasone/formoterol after the study; 66/1964 
(3.4%) were not, and further prescription was 
unknown for 5/1964 (0.3%) patients. Of the 
patients who discontinued the study prematurely, 
a quarter (154/575, 26.8%) subsequently received 
fluticasone/formoterol after study completion, 
whilst half (303/575, 52.7%) did not (unknown 
for the remaining 118, 20.5%). A total of 2047 
(80.6%) patients received fluticasone/formoterol 
further after the study and 369 (14.5%) did not 
(unknown for 123, 4.8%).
The baseline characteristics of the safety popula-
tion are summarized in Table 1. The mean and 
standard deviation (SD) age was 47.7 (17.5) 
years, and most patients (2394, 94.3%) were over 
the age of 18 years. Nearly two thirds (1609, 
63.4%) of the safety population were female and 
2470 (97.8%) were Caucasian. Although 1350 
(60.7%) patients achieved more than 80% pre-
dicted FEV1 at baseline, 1076 (43.8%) had poorly 
controlled asthma (based on ACTTM total score). 
The median duration of asthma was 8.80 years 
(range 0–74.9 years). The most common forms of 
asthma were allergic (1637 patients, 64.5%), 
intrinsic (897, 35.3%) and exercise-induced (335, 
13.2%). Two thirds (1722, 67.8%) of asthma 
cases were classed as persistently moderate in 
Figure 1. Patient disposition.
*Safety population comprises all patients who received at least one dose of study medication.
$Or why fluticasone/formoterol will not be prescribed any further after study completion.
Percentages are of the safety population.
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Table 1. Baseline demographic characteristics (safety population).
n Total (n = 2539)
Age, years 2539  
 Mean (SD) 47.7 (17.5)
 Median (range) 49.0 (11–94)
Age group, n (%) 2539  
 <18 years 145 (5.7)
 ⩾18 years 2394 (94.3)
Sex, n (%) 2539  
 Male 930 (36.6)
 Female 1609 (63.4)
Race, n (%)* 2526  
 Caucasian 2470 (97.8)
 Black 22 (0.9)
 Asian 29 (1.1)
 Other 5 (0.2)
BMI, kg/m2 2536  
 Mean (SD) 28.0 (5.9)
 Median (range) 27.4 (12.2–57.3)
ACTTM, n (%) 2458  
 Controlled 723 (29.4)
 Somewhat controlled 659 (26.8)
 Poorly controlled 1076 (43.8)
Prior treatment, n (%) 2539  
 ICS without LABA 482 (19.0)
 ICS plus LABA (open combination) 235 (9.3)
 LABA without ICS 14 (0.6)
 Beclometasone dipropionate/formoterol 201 (7.9)
 Fluticasone propionate/salmeterol 400 (15.8)
 Budesonide/formoterol 343 (13.5)
 Fluticasone/formoterol 624 (24.6)
 Other 240 (9.5)
(continued)
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n Total (n = 2539)
FEV1, % predicted, n (%) 2225  
 40–60% 200 (9.0)
 >60–80% 675 (30.3)
 >80% 1350 (60.7)
Smoking situation, n (%) 2539 1856 (73.1)
 Nonsmoker 274 (10.8)/409 (16.1)
 Smoker/exsmoker  
Smoking duration$, years 2493 4.9 (10.6)
 Mean (SD)  
Smoking history$, pack-years 2466  
 Mean (SD) 3.3 (9.1)
Asthma duration, years 2538  
 Mean (SD) 11.9 (11.7)
 Median (range) 8.8 (0.0–74.9)
Type of asthma, n (%)‡ 2539  
 Allergic 1637 (64.5)
 Intrinsic 897 (35.3)
 Exercise-induced 335 (13.2)
 Analgesic-induced 13 (0.5)
 Other 62 (2.4)
Severity of asthma, n (%) 2538  
 Intermittent 163 (6.4)
 Persistent mild 480 (18.9)
 Persistent moderate 1722 (67.8)
 Persistent severe 173 (6.8)
*Race information was not collected in France.
$Data from non-smokers were included in calculation of means.
‡A patient may be counted in more than one type of asthma category.
ACT™, Asthma Control Test; BMI, body mass index; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; 
LABA, long-acting β2-agonist; SD, standard deviation.
Table 1. (Continued)
severity. Two thirds of patients (1856, 73.1%) 
were nonsmokers, one in ten (274, 10.8%) were 
current smokers, and 409 (16.1%) were exsmok-
ers. At the baseline visit, 2199 (86.6%) patients 
had at least one concomitant medical condition; 
for example, 66 (2.6%) patients had current 
chronic obstructive pulmonary disease (COPD), 
37 (1.5%) had a respiratory tract infection, 324 
V Backer, A Ellery et al.
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(12.8%) were obese and 803 (31.6%) had allergic 
rhinitis.
Details of asthma medications with which study 
participants were previously treated are presented 
in Table 1. For the 1538 (60.6%) patients switch-
ing to fluticasone/formoterol from another ICS/
LABA treatment prior to the study, the most 
common reason was a lack of efficacy (1150, 
45.3%), followed by a lack of compliance/satis-
faction (319, 12.6%), side effects (137, 5.4%) or 
other reasons (138, 5.4%).
Exposure to asthma medication
The mean (SD) time of on-study exposure to 
fluticasone/formoterol was 344.3 (103.3) days, 
with 1910 (75.2%) patients having on-study 
exposure of at least 12 months. Dosing was sta-
ble in 2116 (83.3%) patients; the proportions of 
patients using only low [approximately 50/5 μg, 
two puffs twice daily (b.i.d.)], medium (approx-
imately 125/5 μg, two puffs b.i.d.) and high 
(approximately 250/10 μg, two puffs bid) dos-
age were 4.8%, 48.0% and 30.6%, respectively. 
Dose increases were recorded in 165 patients 
(6.5%), dose decreases in 113 (4.5%), multiple 
dosage adjustments in 145 (5.7%) and inter-
rupted dosage in 41 (1.6%). Nearly half of 
patients (1152, 45.4%) received a concomitant 
asthma controller medication at least once dur-
ing the study; the most commonly used were 
leukotriene antagonists (675, 26.6%) and sys-
temic corticosteroids (300, 11.8%). Nearly 
three quarters of patients (1845, 72.7%) 
received concomitant asthma rescue medication 
during the study (most commonly SABA: 1559, 
61.4%).
Safety
Overall, 1523 patients (60.0%) experienced a 
total of 4264 AEs, as summarized in Table 2. In 
258 patients (10.2%), investigators considered 
there was a reasonable possibility that AEs (375 
in total) were causally related to fluticasone/for-
moterol treatment. Additional therapy for AEs 
(related or not related) was required for 1223 
patients (48.2%). Most AEs (related or not 
related to treatment) were mild or moderate in 
severity; 570 patients (22.4%) experienced at 
least one mild AE, whilst 634 (25.0%) experi-
enced at least one moderate AE. A total of 508 
severe AEs were reported in 319 patients (12.6%), 
with 29 patients (1.1%) experiencing at least one 
severe AE considered possibly related to flutica-
sone/formoterol (total of 36 events). All serious 
AEs [SAEs; 139, in 107 (4.2%) patients] were 
considered not to be related to fluticasone/formo-
terol. Four patients (0.2%) died during the study; 
these deaths were attributed to bronchopneumo-
nia, liver metastases, cerebrovascular accident 
and pulmonary embolism, respectively. None of 
the deaths were considered related to fluticasone/
formoterol.
The most frequently reported AEs by preferred 
term were asthma exacerbation (647 events in 
435 patients, 17.1%), nasopharyngitis (199 
events in 165 patients, 6.5%), bronchitis (189 
events in 149 patients, 5.9%), and lower res-
piratory tract infection (143 events in 93 
patients, 3.7%). The most frequently observed 
severe AEs were asthma exacerbation (248 
patients, 9.8%), lower respiratory tract infec-
tion (10 patients, 0.4%) and bronchitis (8 
patients, 0.3%).
The rates of AEs considered related to flutica-
sone/formoterol were low and are summarized in 
Table 3. The only AEs that were considered 
related to fluticasone/formoterol that occurred in 
more than 1% patients were asthma exacerbation 
(59 AEs in 50 patients, 2.0%), dysphonia (47 
AEs in 46 patients, 1.8%), and cough (28 AEs in 
28 patients, 1.1%).
AEs of special interest (Supplementary Table 1) 
were experienced by 1247 (49.1%) patients, pri-
marily local immunosuppressive effects/infec-
tions (899 patients, 35.4%). AEs of special 
interest that were assessed by the physician as 
having a reasonable possibility of a causal rela-
tionship to fluticasone/formoterol were reported 
in 211 patients (8.3%). The most common of 
these were ‘respiratory AEs including cough and 
paradoxical bronchospasm’ (82 patients, 3.2%, 
note that no cases of paradoxical bronchospasm 
were recorded), ‘local immunosuppressive 
effects, infections’ (57 patients, 2.2%), and 
‘asthma worsening/asthma exacerbation’ (50 
patients, 2.0%).
Effectiveness
Asthma control. During the course of the study, 
asthma control improved compared with that 
achieved with the previous asthma treatment. The 
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mean (SD) ACTTM total score at baseline, related 
to the prior asthma treatment, was 16.3 (4.8). 
The mean total score increased to 19.2 (4.2) at 1 
month (n = 800), and the improvement was sus-
tained throughout the study period, with a mean 
(SD) score of 20.4 (4.3) at the end of the study 
(Table 4). The mean (SD) change from baseline 
ranged from 3.1 (4.7; at 3 months, n = 1356) to 
4.6 (5.1; at 12 months, n = 1771). Correspond-
ingly, the proportion of patients with controlled 
asthma, that is, with ACTTM total score ⩾ 20, also 
increased from 29.4% at baseline to 67.4% at end 
of study (Figure 2).
Severe asthma exacerbations
In the 12 months prior to enrolment in the study, 
1629 (64.2%) patients had no severe asthma 
exacerbations. The remaining 909 (35.8%) 
patients experienced up to 12 severe asthma exac-
erbations; 88 (3.5%) reported 6 or more, whilst 
461 (18.2%) experienced only 1. During the 
study period on fluticasone/formoterol treatment, 
2291 (90.2%) patients experienced no severe 
asthma exacerbations. In the 248 (9.8%) patients 
who experienced a severe asthma exacerbation, 
the maximum count was seven (in one patient, 
<0.1%); most (166, 6.5%) experienced only one.
Table 2. Overall summary of adverse events (safety population).
Total (n = 2539)
Patients with ⩾1 AE, n (%) 1523 (60.0)
 Number of AEs 4264
Patients with ⩾1 related* AE, n (%) 258 (10.2)
 Number of related* AEs 375
Patients with ⩾1 severe AE, n (%) 319 (12.6)
 Number of severe AEs 508
Patients with ⩾1 related* severe AE, n (%) 29 (1.1)
 Number of related* severe AEs 36
Patients with ⩾1 SAE, n (%) 107 (4.2)
 Number of SAEs 139
Patients who died$ 4 (0.2)
Patients with ⩾1 AE 152 (6.0)
 Leading to study/treatment discontinuation‡ 1223 (48.2)
 Requiring additional therapy 39 (1.5)
 Leading to dose reduction 28 (1.1)
 Leading to dose interruption 134 (5.3)
 Leading to dose increase  
Patients with ⩾1 related* AE
leading to study/treatment discontinuation‡
of special interest
112 (4.4)
211 (8.3)
*Investigator considered reasonable possibility of causal relationship to investigational medicinal product.
$Deaths were not considered to be possibly related to fluticasone/formoterol.
‡An AE was considered as leading to discontinuation from study if other action taken contains ‘discontinued from 
observation’ or if action taken with fluticasone/formoterol is ‘withdrawn’.
Note that a patient may have findings in more than one category.
AE, adverse event; SAE, serious adverse event.
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Table 3. Patients with adverse events considered to be related* to fluticasone/formoterol (observed in more 
than two patients; safety population).
System organ class
Preferred term
Total (n = 2539)
Cardiac disorders, n (%)
 Palpitations 14 (0.6)
 Tachycardia 7 (0.3)
Gastrointestinal disorders, n (%)
 Dry mouth 4 (0.2)
 Dyspepsia 3 (0.1)
 Nausea 6 (0.2)
General disorders, n (%)
 Chest discomfort 5 (0.2)
Infections and infestations, n (%)
 Bronchopneumonia 3 (0.1)
 Lower respiratory tract infection 7 (0.3)
 Nasopharyngitis 3 (0.1)
 Oral candidiasis 17 (0.7)
 Oral fungal infection 4 (0.2)
 Oropharyngeal candidiasis 3 (0.1)
 Respiratory tract infection 3 (0.1)
 Upper respiratory tract infection 4 (0.2)
Musculoskeletal and connective tissue disorders, n (%)
 Back pain 3 (0.1)
 Muscle spasms 7 (0.3)
Nervous system disorders, n (%)
 Dizziness 3 (0.1)
 Headache 10 (0.4)
 Tremor 16 (0.6)
Respiratory, thoracic and mediastinal disorders, n (%)
 Asthma 50 (2.0)
 Cough 28 (1.1)
 Dysphonia 46 (1.8)
 Dyspnoea 5 (0.2)
(Continued)
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Table 4. Asthma Control Test scores (ACTTM).
Test component Baseline 
(n = 2456) 
Month 12 
(n = 1783) 
End of study 
(LOCF) 
(n = 2220)
Change from baseline 
to end of study (LOCF) 
(n = 2197)
Mean (SD) Mean (SD) Mean (SD) Mean (SD) 95% CI
Total score 16.3 (4.8) 20.8 (4.0) 20.4 (4.3) 4.2 (5.2)* 3.93, 4.37
Ability to perform 
daily activities
3.4 (1.1) 4.2 (0.9) 4.1 (0.9) 0.7 (1.2)* 0.68, 0.77
Shortness of 
breath
3.1 (1.3) 4.0 (1.0) 3.9 (1.1) 0.9 (1.4)* 0.83, 0.95
Sleep disturbances 
due to asthma
3.3 (1.4) 4.3 (1.0) 4.2 (1.1) 0.9 (1.5)* 0.83, 0.95
Necessity to use a 
rescue medication
3.2 (1.3) 4.2 (1.1) 4.1 (1.1) 0.8 (1.4)* 0.79, 0.91
Subject 
assessment of 
asthma control
3.3 (1.1) 4.2 (0.8) 4.1 (0.9) 0.8 (1.2)* 0.75, 0.85
*p < 0.001 (paired t test).
Each of the five components assessed on a 5-point scale; total score may range from 5 to 25, with a higher score indicating 
better control.
CI, confidence interval; LOCF, last observation carried forward, up to 12 months; SD, standard deviation.
System organ class
Preferred term
Total (n = 2539)
 Oropharyngeal pain 13 (0.5)
 Upper-airway cough syndrome 3 (0.1)
Vascular disorders, n (%)
 Hypertension 3 (0.1)
*Investigator considered reasonable possibility of causal relationship to investigational medicinal product.
A patient may have more than one adverse event in any category. Highest causal relationship to study medication is 
counted if an adverse event is reported more than once by the same subject. Adverse events were coded using MedDRA 
version 16.0 (March 2013, MedDRA MSSO, McLean, VA, USA).
Table 3. (Continued)
During the study, a total of 370 severe asthma 
exacerbations were recorded over a cumulative 
treatment exposure of 2442.1 years; this trans-
lates to an overall annualized rate of 0.15 for 
severe asthma exacerbations whilst receiving fluti-
casone/formoterol.
Quality of life
The mean (SD) total AQLQ score increased from 
4.7 (1.2) at baseline to 5.6 (1.1) at the end of the 
study (Table 5). Improvements were also seen in 
all four components of the AQLQ.
Lung function
All measured lung function parameters increased 
between baseline and end of study, as shown in 
Supplementary Table 2. The mean (SD) baseline 
and end-of-study values, respectively, for FEV1 
were 2.58 l (0.86) and 2.72 l (0.93); for FVC, 
3.32 l (1.09) and 3.43 l (1.12); for FEV1/FVC, 
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0.78 (0.12) and 0.80 (0.12); and for PEF, 356.1 l/
min (124.7) and 377.0 l/min (127.9). Changes in 
percent predicted values for these parameters 
improved accordingly (Supplementary Table 2).
Satisfaction with asthma treatment
Physicians indicated improvements in their rating 
of the efficacy and tolerability of fluticasone/for-
moterol compared with the prior treatment (base-
line), as well as in their assessment of their patients’ 
adherence to the treatment [Figure 3(a)]. The 
proportion of physicians rating treatment efficacy 
as ‘good’ or ‘very good’ increased from 29.8% at 
baseline to 88.3% at end of study, with increases 
from 66.7% to 94.4% for tolerability and 64.6% 
to 88.8% for adherence. Patient-rated satisfaction 
also indicated improvements in opinions of effi-
cacy and safety [Figure 3(b)]. The proportion of 
patients rating efficacy as ‘good’ or ‘very good’ 
Figure 2. Asthma control status at baseline and end 
of study (last observation carried forward up to 12 
months).
Asthma control based on ACTTM total score (controlled, 
ACTTM ⩾ 20; somewhat controlled, ACTTM 16–19; poorly 
controlled, ACTTM ⩽ 15). Percentages are based on number 
of patients with data available at respective time point: 
baseline, n = 2456; LOCF, n = 2220.
ACTTM, Asthma Control Test; LOCF, last observation carried 
forward, up to 12 months.
Table 5. Asthma Quality of Life Questionnaire scores.
Baseline End of study (LOCF) Change from baseline
Total score
 n 2381 1781 1772  
 Mean (SD) 4.69 (1.23) 5.64 (1.10) 1.01 (1.12)* 0.96, 1.06
Activities limitation score
 n 2379 1779 1768  
 Mean (SD) 4.82 (1.25) 5.66 (1.11) 0.92 (1.09)* 0.87, 0.97
Emotional function score
 n 2379 1781 1771  
 Mean (SD) 4.82 (1.44) 5.78 (1.19) 1.00 (1.32)* 0.94, 1.06
Environmental stimuli score
 n 2379 1780 1769  
 Mean (SD) 4.60 (1.44) 5.46 (1.30) 0.92 (1.27)* 0.86, 0.98
Symptoms score
 n 2381 1782 1773  
 Mean (SD) 4.55 (1.30) 5.61 (1.13) 1.14 (1.26)* 1.08, 1.19
*p < 0.001 (paired t test).
Total AQLQ and components are mean ratings on a 7-point scale; each score may range from 1 to 7, with a higher score 
indicating less impairment. Note that n is for total score; these differed slightly (by no more than four patients) for most 
component scores.
AQLQ, Asthma Quality of Life Questionnaire; CI, confidence interval; LOCF, last observation carried forward, up to 12 
months; SD, standard deviation.
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Figure 3. Satisfaction with treatment rated by (a) physicians and (b) patients.
Percentages are based on number of patients with data available at each respective time point.
LOCF, last observation carried forward, up to 12 months.
increased from 37.0% to 87.8%; the proportion 
for tolerability increased from 65.6% to 92.5%.
On-study healthcare resource use
The mean (SD) number of days of absence from 
work/school/college/university or of days with 
inability to perform everyday activities due to 
asthma within a 30-day period decreased from 
1.4 (3.9) at baseline to 0.3 (2.0) at the end of 
study; the median (range) was 0 (0–30) days at 
both time points.
During the 12-month observation period, in 
which there was a total on-treatment exposure 
duration of 874,188 days (2393.4 patient-years), 
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the total number of asthma-related unscheduled 
visits was 659, with a mean (SD) annualized rate 
of 0.36 (1.33) and range 0.0–22.8; the total num-
ber of asthma-related emergency visits was 72, 
with mean (SD) annualized rate of 0.04 (0.43) 
and range 0.0–15.2; the total number of asthma-
related hospital admissions was 24, with mean 
(SD) annualized rate of 0.01 (0.28) and range 
0.0–12.2, and the total number of asthma-related 
days spent at hospital was 138, with mean (SD) 
annualized rate of 0.1 (2.58) and range 0.0–
121.8. The numbers of individual events include 
participating patients who may have contributed 
more than one event to each count within the 
timescale analysed.
During the study, 373 (14.7%) patients had at 
least one recorded use of systemic corticosteroid 
due to asthma, and 479 (18.9%) patients had at 
least one recorded use of antibiotic due to lung/
lower respiratory tract infection.
Discussion
The value of supplementing the findings of classi-
cal RCTs with observational data from real-world 
studies is increasingly recognized.22 RCTs main-
tain a vital role in supporting the approval of new 
products, owing to their high internal validity and 
the robustness of evidence they generate.23 More 
pragmatic trials, however, provide an opportunity 
to confirm the efficacy and safety of these prod-
ucts in populations that are representative of true 
clinical practice, by including patients who would 
typically be excluded from RCTs, such as those 
who smoke, are overweight, or have comorbidi-
ties generally excluded in RCTs.21–23 The need 
for real-world evidence is especially relevant in 
respiratory medicine, where treatment efficacy 
relies upon good inhaler technique and patient 
engagement in treatment regimens.23 It is impor-
tant to demonstrate the level of effectiveness that 
can be achieved in the absence of the rigorous 
training in inhaler use that typically features in the 
design of RCTs in patients with asthma. In recog-
nition of these issues, a number of pragmatic 
RCTs and observational studies have been con-
ducted in heterogeneous asthma populations in 
recent years.25–27
Together with a 12-month non-interventional 
study of fluticasone/formoterol conducted in 
Germany (ffAiRNeSS),28 the PASS reported here 
was conducted as part of an agreed EU RMP. 
The current study was designed with the primary 
objective of collecting safety information during 
routine clinical use of fluticasone/formoterol, and 
also monitored the effectiveness of this ICS/
LABA in achieving asthma control in real-world 
practice across eight European countries. The 
study population was inclusive of patients who 
would have been excluded from the pivotal RCTs 
that supported approval of fluticasone/formo-
terol; for example, smokers (10.8%), and patients 
with concurrent medical conditions at the base-
line visit such as COPD (2.6%) or respiratory 
tract infection (1.5%).
Notwithstanding the diversity of the enrolled 
population, incorporating patients with comor-
bidities and with ‘real-world’ behaviour relating 
to inhaler technique and adherence to medica-
tion, the safety profile of fluticasone/formoterol 
was consistent with the RCT data. Most AEs 
recorded in the PASS were considered not to be 
related to fluticasone/formoterol and few patients 
experienced SAEs (4.2%; none related to treat-
ment). The rate of SAEs was comparable to that 
reported in other 12-month studies of fluticasone/
formoterol, such as the open-label phase III study 
(2.1% reported SAEs)9 and the real-world ffAiR-
NeSS study (4.0%),28 and the 13% of patients 
who reported SAEs during fluticasone furoate/
vilanterol treatment in the asthma Salford Lung 
Study, for example.29 The most common AEs 
considered to be related to fluticasone/formoterol 
were asthma exacerbation (2.0%) and dysphonia 
(1.8%), which mirrors the finding in the 12-month 
open-label phase III study.9 Dysphonia was also 
the most common treatment-related AE in the 
ffAiRNeSS study.28 The rates of bronchopneu-
monia and oropharyngeal candidiasis were low 
(0.1% in both cases).
Analysis of effectiveness of fluticasone/formoterol 
in this PASS revealed improvements similar to 
those seen in other observational studies, and 
indeed RCTs. The change in the mean total 
ACTTM score from baseline to the end of this 
study (from 16.3 to 20.4) is similar to the change 
seen over 12 months in the ffAiRNeSS study 
(from 16.3 to 19.8).28 Correspondingly, the 
increase in the proportion of patients with con-
trolled asthma (total ACTTM score ⩾ 20) from 
29.4% at baseline to 67.4% at end of study is simi-
lar to the increases observed with fluticasone/for-
moterol in the ffAiRNeSS study (30.9–62.4%).28 
In the asthma Salford Lung Study, 28% of patients 
Therapeutic Advances in Respiratory Disease 12
14 journals.sagepub.com/home/tar
had controlled asthma (ACTTM total score of 
⩾20) at baseline.29 At 24 weeks, 71% of patients 
with uncontrolled asthma at baseline had achieved 
asthma control or had an increase of ⩾3 points in 
ACTTM score from baseline; statistically signifi-
cant findings were also seen at 12 months. It is 
important to note the wider definition for treat-
ment success used in the Salford Lung Study 
compared with the current study.29,30 The mean 
AQLQ score in the current study increased from 
4.7 at baseline to 5.6 at end of study; once more, 
an improvement consistent with that reported in 
the ffAiRNeSS study (4.7–5.6).28 The pivotal 
RCTs of fluticasone/formoterol typically featured 
predose FEV1 as the primary outcome. In a phase 
III trial with fluticasone/salmeterol as an active 
comparator, for example, the least-squares mean 
(95% CI) change from baseline in predose FEV1 
with fluticasone/formoterol at 12 weeks was 
0.196 l (0.12, 0.28).4 At 3 months in the current 
study (data for this time point not presented ear-
lier), there was a mean (95% CI) change from 
baseline in FEV1 of 0.112 l (0.09, 0.14). It is not 
appropriate to directly compare these two values, 
as the former study presented least-squares mean 
data; nonetheless, the current data support a ben-
eficial effect of fluticasone/formoterol on lung 
function in real-world practice.
During the observational period of this study, 
9.8% patients experienced at least one severe 
asthma exacerbation, compared with 35.8% in 
the 12 months prior to the start of the study. This 
on-study incidence of severe asthma exacerba-
tions was higher than that observed in the ffAiR-
NeSS study (5.9%)28 or another 12-month phase 
III open-label study (2%),9 but the observed 
reduction in exacerbation rate is nonetheless 
encouraging given the broad population and real-
world setting of the current study. Analysis of 
pooled clinical data from two open-label trials of 
fluticasone/formoterol has suggested that this 
treatment is associated with a lower rate of exac-
erbations requiring oral corticosteroids than other 
ICS/LABA combinations.31
The current study provided a useful insight into 
the basis for treatment decisions. Nearly half 
(45.3%) of patients who were already treated 
with ICS/LABA switched to fluticasone/formo-
terol on the basis of a lack of efficacy with their 
previous asthma medication. The proportion of 
physicians rating treatment efficacy as ‘good’ or 
‘very good’ increased from 29.7% to 88.3% from 
baseline to the end of the fluticasone/formoterol 
treatment period, and the patient ratings were 
similar (37.0% to 87.8%). These improvements 
are reflected in the high proportion of patients 
who continued to received fluticasone/formoterol 
after the study (96% of those who completed the 
study and 81% overall).
By including patients who may not have met the 
inclusion criteria for pre-approval RCTs, this 
PASS has provided data on the long-term safety 
and effectiveness of fluticasone/formoterol that 
are more representative of patients observed in 
normal clinical practice than previously available. 
For example, the study population contained 
patients with comorbid conditions such as diabe-
tes mellitus (71 patients, 2.8%). Whilst not con-
traindicated, conditions such as diabetes present 
a need for additional caution when prescribing 
fluticasone/formoterol.24 This was relevant to 
only a very small proportion of the overall study 
population; nonetheless, documented data on 
such patients are valuable for informing practice.
As a PASS of non-interventional design, this 
study was inevitably associated with certain limi-
tations. Patient visits and assessments were per-
formed according to local clinical practice or 
standard of care leading to a high variability in the 
frequency and schedule of patient visits and the 
assessments conducted at these visits. 
Consequently, the availability of data at the pre-
specified time points varied considerably. LOCF 
was used to manage missing data for the end-of-
study assessments of effectiveness, thereby pool-
ing the data of the last known patient status under 
fluticasone/formoterol treatment within the study, 
regardless of time of discontinuation from, or 
completion of, the study.32 Furthermore, since 
the primary objective of our research was to col-
lect data on the safety of fluticasone/formoterol, 
the study was not powered for analysis of effec-
tiveness. Thus, results of the exploratory inferen-
tial statistical analyses done for the effectiveness 
parameters (for example, in ACTTM and AQLQ 
scores, and lung function parameters) must there-
fore be interpreted in this context.
Conclusion
This 12-month PASS, conducted as part of an 
agreed EU RMP, supports the use of fluticasone/
formoterol in clinical practice as a well tolerated 
and efficacious therapy for patients with moderate 
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to severe asthma. No specific safety signals were 
observed. Fluticasone/formoterol was associated 
with improved asthma control and reduced inci-
dence of severe asthma exacerbations compared 
with patients’ prior asthma treatment. These 
improvements were reflected in both physician- 
and patient-rated assessments of treatment effi-
cacy and tolerability.
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